Rathbone Brothers plc boosted its position in Adaptimmune Therapeutics PLC – (NASDAQ:ADAP) by 27.9% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 285,722 shares of the biotechnology company’s stock after purchasing an additional 62,292 shares during the quarter. Rathbone Brothers plc’s holdings in Adaptimmune Therapeutics were worth $1,229,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the business. BlackRock Inc. raised its position in Adaptimmune Therapeutics by 1.6% during the third quarter. BlackRock Inc. now owns 775,405 shares of the biotechnology company’s stock worth $10,514,000 after acquiring an additional 12,113 shares in the last quarter. SG Americas Securities LLC raised its position in Adaptimmune Therapeutics by 157.3% during the fourth quarter. SG Americas Securities LLC now owns 20,004 shares of the biotechnology company’s stock worth $115,000 after acquiring an additional 12,229 shares in the last quarter. Virtus ETF Advisers LLC raised its position in Adaptimmune Therapeutics by 54.8% during the fourth quarter. Virtus ETF Advisers LLC now owns 58,223 shares of the biotechnology company’s stock worth $335,000 after acquiring an additional 20,620 shares in the last quarter. Henry James International Management Inc. bought a new stake in Adaptimmune Therapeutics during the fourth quarter worth $144,000. Finally, Acadian Asset Management LLC bought a new stake in Adaptimmune Therapeutics during the fourth quarter worth $219,000. Institutional investors and hedge funds own 65.79% of the company’s stock.

Several research firms have issued reports on ADAP. BidaskClub raised shares of Adaptimmune Therapeutics from a “sell” rating to a “hold” rating in a research report on Wednesday, February 13th. Zacks Investment Research lowered shares of Adaptimmune Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday, February 1st. Two equities research analysts have rated the stock with a sell rating, three have given a hold rating and four have assigned a buy rating to the company’s stock. Adaptimmune Therapeutics has an average rating of “Hold” and a consensus target price of $6.53.

NASDAQ ADAP opened at $3.63 on Friday. The company has a debt-to-equity ratio of 0.12, a quick ratio of 8.55 and a current ratio of 8.55. Adaptimmune Therapeutics PLC – has a 1 year low of $3.51 and a 1 year high of $14.54. The firm has a market cap of $380.03 million, a price-to-earnings ratio of -3.78 and a beta of 1.35.

Adaptimmune Therapeutics (NASDAQ:ADAP) last issued its quarterly earnings data on Monday, May 6th. The biotechnology company reported ($0.24) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.28) by $0.04. Adaptimmune Therapeutics had a negative net margin of 161.09% and a negative return on equity of 45.03%. Equities research analysts anticipate that Adaptimmune Therapeutics PLC – will post -1.2 EPS for the current year.

WARNING: “Adaptimmune Therapeutics PLC – (ADAP) Position Boosted by Rathbone Brothers plc” was originally published by Watch List News and is the sole property of of Watch List News. If you are reading this report on another publication, it was copied illegally and republished in violation of United States and international trademark and copyright laws. The legal version of this report can be viewed at https://www.watchlistnews.com/adaptimmune-therapeutics-plc-adap-position-boosted-by-rathbone-brothers-plc/3020984.html.

Adaptimmune Therapeutics Profile

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States. The company's specific peptide enhanced affinity receptor T-cell platform enables it to identify cancer targets. It is involved in developing ADP-A2M10 that is in the phase I clinical trials for the treatment of non-small cell lung cancer (NSCLC), as well as urothelial, melanoma, and head and neck cancers; ADP-A2M4 that is in phase I clinical trial for solid tumor indication that include urothelial, melanoma, head and neck, ovarian, NSCLC, esophageal, gastric, synovial sarcoma, and myxoid round cell liposarcoma cancers; and ADP-A2AFP that is in phase I clinical trial for hepatocellular carcinoma.

Featured Story: Forex

Want to see what other hedge funds are holding ADAP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Adaptimmune Therapeutics PLC – (NASDAQ:ADAP).

Institutional Ownership by Quarter for Adaptimmune Therapeutics (NASDAQ:ADAP)

Receive News & Ratings for Adaptimmune Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adaptimmune Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.